Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Apc deficiency predisposes to renal carcinoma in the mouse


Deregulation of Wnt signalling has recently been implicated in human renal cancer. Here, we directly test this association by using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine renal epithelium. Mice homozygous for a conditional Apc allele were intercrossed with mice transgenic for Cre recombinase under control of the Cyp1A promoter, which delivers constitutive recombination within a proportion of cells in the renal epithelium. Inactivation of Apc leads to the accumulation of nuclear β-catenin and the rapid development of multiple dysplastic foci. Renal carcinoma was observed with an earliest onset of 4 months. This predisposition was accelerated by p53 deficiency, reducing the earliest onset to 2 months. Compared to other murine models of kidney neoplasia, this represents particularly rapid onset of disease, and so implicates an important role for Apc in suppressing renal carcinoma.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3


  • Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T and Clevers H . (2002). Cell, 111, 251–263.

  • Bardeesy N, Falkof D, Petruzzi M-J, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T and Pelletier J . (1994). Nat. Genet., 7, 91–97.

  • Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K and Tomita Y . (2000). Clin. Cancer Res., 6, 460–466.

  • Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH . (1993). Nature, 362, 849–851.

  • Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J, Takahashi M, Todo S and Moriuchi T . (2000). Am. J. Pathol., 156, 1997–2005.

  • Gallagher RCJ, Hay T, Meniel V, Naughton C, Anderson TJ, Shibata H, Ito M, Clevers H, Noda T, Sansom OJ, Mason JO and Clarke AR . (2002). Oncogene, 21, 6446–6457.

  • Guo L, Kuroda N, Miyazaki E, Hayashi Y, Toi M, Naruse K, Hiroi M, Ashida S, Shuin T and Enzan H . (2001). Oncol. Rep., 8, 521–526.

  • Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ and Winton DJ . (2004). Gasteroenterology, 126, 1236–1246.

  • Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, Finniear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I and Nakamura Y . (1991). Science, 253, 661–665.

  • Kleymenova E, Everitt JI, Pluta L, Portis M, Gnarra JR and Walker CL . (2004). Carcinogenesis, 25, 309–315.

  • Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O and Noda T . (1999). Cancer Res., 59, 1206–1211.

  • Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T and Hino O . (2001). Proc. Natl. Acad. Sci. USA, 98, 8762–8767.

  • Koesters R, Niggli F, von Knebel Doeberitz M and Stallmach T . (2003). J. Pathol., 199, 68–76.

  • Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J and von Knebel Doeberitz M . (1999). Cancer Res., 59, 3880–3882.

  • Kusafuka T, Miao J, Kuroda S, Udatsu Y and Yoneda A . (2002). Int. J. Mol. Med., 10, 395–399.

  • Menke AL, Clarke AR, Leitch A, Ijpenberg A, Williamson KA, Spraggon L, Harrison DJ and Hastie ND . (2002). Cancer Res., 62, 6615–6620.

  • Onda H, Lueck A, Marks PW, Warren HB and Kwiatkowski DJ . (1999). J. Clin. Invest., 104, 687–695.

  • Pecina-Slaus N, Pavelic K and Pavelic J . (1999). J. Mol. Med., 77, 446–453.

  • Qian CN, Knol J, Igarashi P, Lin F, Zylstra U, Teh BT and Williams BO . (2005). J. Biol. Chem., 280, 3938–3945.

  • Saadi-Kheddouci S, Berrebi D, Romagnolo B, Cluzeaud F, Peuchmaur M, Kahn A, Vandewalle A and Perret C . (2001). Oncogene, 20, 5972–5981.

  • Sansom OJ, Reed K, Hayes AJ, Ireland H, Brinkmann H, Newton IP, Batlle E, Simon-Assmann P, Clevers H, Nathke IS, Clarke AR and Winton DJ . (2004). Genes Develop, 18, 1385–1390.

  • Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T, Toyoshima K, Kanamaru R, Kanegae Y, Saito I, Nakamura Y, Shiba K and Noda T . (1997). Science, 278, 120–123.

  • Soriano P . (1999). Nat. Genet., 21, 70–71.

  • Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D and Pietsch T . (2003). Lab Invest., 83, 429–434.

  • Zang T, Zhuang L, Zhang Z, Xin D and Guo Y . (2001). Chin. Med. J., 114, 152–154.

  • Zhu X, Kanai Y, Saito A, Kondo Y and Hirohashi S . (2000). Pathol. Int., 50, 945–952.

Download references


We thank Mark Bishop for technical assistance. This work was supported by the Wales Gene Park and grants from CR-UK and the BBSRC.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alan R Clarke.

Additional information

Supplementary Information accompanies the paper on oncogene website (

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sansom, O., Griffiths, D., Reed, K. et al. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 24, 8205–8210 (2005).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Apc
  • kidney
  • Wnt
  • Cre
  • renal cancer

Further reading


Quick links